History and Investment
The company's SaaS model improves the success rates of bringing innovative drugs to patients faster, at a lower cost, and with greater safety. InsilicAll's mission is to deliver the best technology with the lowest impact (ESG) and eliminate animal experimentation in its clients' processes (cruelty-free). The company integrates AI, computation, and biological automation to accelerate the design of new molecules and protein therapeutics.
InsilicAll was founded in 2019 and has since made significant strides in the field of drug discovery. In 2017, the company was awarded second place in the Biostartup Lab program of Biominas Brazil and was also a finalist in InovAtiva Brasil, demonstrating early recognition of its potential.
The company received its first capital investment from BiotechTown in 2019, and subsequently graduated from the institution's Business Development Program. This provided the necessary resources for InsilicAll to develop its minimum viable product (MVP) of a drug discovery platform with three applications.